Zentalis Pharmaceuticals, Inc. Earnings Per Share, Basic and Diluted
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Earnings Per Share, Basic and Diluted of -$1.24 per share for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-05-17
- Zentalis Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$1.24.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$1.01.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.91.
- Zentalis Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.78.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | -$1.24 10-Q · filed 2021-05-17 | -$2.25 derived: net income ÷ weighted average shares · filed 2022-05-05 | -$3.17 derived: net income ÷ weighted average shares · filed 2022-05-05 | -$3.97 derived: net income ÷ weighted average shares · filed 2022-05-05 |
| 2020-12-31 | -$1.01 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$1.92 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$2.72 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$4.19 derived: net income ÷ weighted average shares · filed 2023-03-01 |
| 2020-09-30 | -$0.91 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$1.70 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$3.21 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$4.41 derived: net income ÷ weighted average shares · filed 2022-02-24 |
| 2020-06-30 | -$0.78 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$2.53 derived: net income ÷ weighted average shares · filed 2021-08-12 | -$3.79 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$5.46 derived: net income ÷ weighted average shares · filed 2022-02-24 |
| 2020-03-31 | -$2.88 10-Q · filed 2021-05-17 | -$5.48 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$7.68 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$9.55 derived: net income ÷ weighted average shares · filed 2022-02-24 |
| 2019-12-31 | -$2.60 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$4.80 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$6.67 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$8.16 derived: net income ÷ weighted average shares · filed 2022-02-24 |
| 2019-09-30 | -$2.20 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$4.07 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$5.56 derived: net income ÷ weighted average shares · filed 2020-11-09 | |
| 2019-06-30 | -$1.87 derived: net income ÷ weighted average shares · filed 2021-03-25 | -$3.36 derived: net income ÷ weighted average shares · filed 2020-08-13 | ||
| 2019-03-31 | -$1.49 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |